Ouster, Inc. (OUST)

Intra-Cellular Therapies Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Aug 13, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	1,914	608	312	159	892	338
Market Cap Growth	193.44%	94.87%	95.76%	-82.13%	164.40%	-
Enterprise Value	1,663	479	179	63	684	380
Last Close Price	28.70	12.22	7.67	8.63	52.00	135.00
PS Ratio	11.70	5.47	3.75	3.89	26.58	17.85
PB Ratio	7.51	3.36	1.74	0.93	3.42	-9.20
P/TBV Ratio	9.11	3.73	2.01	1.56	4.77	-
EV/Sales Ratio	13.22	4.31	2.15	1.53	20.36	20.12
Debt / Equity Ratio	0.08	0.11	0.39	0.33	0.07	-0.59
Asset Turnover	0.40	0.37	0.28	0.15	0.19	0.44
Inventory Turnover	4.35	3.56	3.51	2.23	3.99	4.77
Quick Ratio	2.85	2.48	2.82	4.64	8.81	0.73
Current Ratio	3.17	2.80	3.22	5.51	9.38	1.01
Return on Equity (ROE)	-46.96%	-53.83%	-212.99%	-64.10%	-83.91%	-
Return on Assets (ROA)	-20.53%	-21.46%	-38.13%	-32.24%	-35.20%	-75.00%
Return on Capital (ROIC)	-27.20%	-28.89%	-46.87%	-35.80%	-47.02%	-406.63%
Earnings Yield	-4.91%	-15.96%	-119.86%	-86.91%	-10.53%	-31.64%
FCF Yield	-0.85%	-6.16%	-45.14%	-72.83%	-8.44%	-13.52%
Buyback Yield / Dilution	-21.79%	-25.76%	-108.19%	-32.86%	-649.86%	-141.65%

Updated May 9, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q